STXS241220P5000
- 0.00
- 0.000.00%
Stereotaxis Newsroom
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5
Strategic Partnerships and Regulatory Advancements Propel Stereotaxis to Buy Rating
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5
Piper Sandler Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
Piper Sandler Releases a Buy Rating on Stereotaxis (STXS)
TD Cowen Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $5
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
Lake Street Sticks to Its Buy Rating for Stereotaxis (STXS)
Lake Street Maintains Stereotaxis(STXS.US) With Buy Rating, Maintains Target Price $4
Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)
A Quick Look at Today's Ratings for Stereotaxis(STXS.US), With a Forecast Between $4 to $5
A Quick Look at Today's Ratings for Stereotaxis(STXS.US), With a Forecast Between $4 to $5
Piper Sandler Sticks to Their Buy Rating for Stereotaxis (STXS)
Analysts Are Bullish on Top Healthcare Stocks: Stereotaxis (STXS), Neumora Therapeutics, Inc. (NMRA)
Analysts' Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)
Analysts Are Bullish on Top Healthcare Stocks: Joint (JYNT), Stereotaxis (STXS)
Lake Street Keeps Their Buy Rating on Stereotaxis (STXS)
Stereotaxis Set for Breakout Growth: Buy Rating Affirmed Amidst Regulatory Advances and Robust Financials